Paganini–Miozzo Syndrome: A New Variant with More Distinct Clinical Features in a Colombian Child
Year: 2026
Type: article
Study design: Case Report
Abstract: Paganini-Miozzo syndrome (MRXSPM) is an extremely rare X-linked neurodevelopmental disorder characterized by global developmental delays, intellectual disability, high myopia, and mild dysmorphic features.1 The syndrome results from pathogenic variants in the HS6ST2 gene on chromosome Xq26, which encodes heparan sulfate 6-O-sulfotransferase 2, an enzyme essential for neuronal development and cell signaling.1,2 Although the core phenotype includes neurodevelopmental impairment and ocular abnormalities, recent reports have expanded the spectrum to include neurological and endocrine manifestations.3 Experimental studies have further shown that HS6ST2 cooperates with HS6ST1 during embryogenesis to regulate gonadotropin-releasing hormone (GnRH) neuron formation and migration through FGF8-and SEMA3A-dependent pathways, supporting its broader role in neurodevelopment and neuroendocrine function.4 To date, only 4 patients carrying 3 different HS6ST2 variants have been reported worldwide, including 2 Italian monozygotic twins, 1 Iranian patient, and 1 Chinese patient.[1][2][3] Consequently, genotype-phenotype correlations and the clinical spectrum of Paganini-Miozzo syndrome remain poorly defined.Here, we report the clinical and molecular findings of a Colombian patient harboring a novel HS6ST2 variant, thereby expanding both the mutational and phenotypic spectrum of this disorder.To our knowledge, this represents the fifth reported case worldwide and the first from the American continent.A 2-year-old Colombian boy was referred to our team for evaluation of global developmental delay and suspected genetic disease.He was born following an uncomplicated second pregnancy by elective cesarean delivery at 38 weeks of gestation, with a birth weight of 3500 g, and was vigorous at birth.His neonatal course was notable only for prolonged breastfeeding-associated jaundice (maximum bilirubin: 8 mg/dL), which resolved without hospitalization.He achieved independent walking at 12 months and spoke his first words at 10 months.No dysmorphic facial features were noted on physical examination.At 4 months of age, he was hospitalized for 5 days because of bronchiolitis.There was no history of seizures or head trauma.The patient subsequently developed behavioral problems, including frequent tantrums and features suggestive of autism spectrum disorder (ASD).Neuropsychological evaluation using the WPPSI-III, CUMANIN, Autism Screening Questionnaire, CARS, ICAP, and DSM-5 criteria supported a diagnosis of high-functioning ASD (Level 1).Color Doppler echocardiography was unremarkable.Neurological examination showed preserved muscle strength, mild hypotonia, ligamentous hyperlaxity, fluent speech, and appropriate interaction.He subsequently received multidisciplinary rehabilitation, including occupational, speech, physical, and psychological therapies.Electroencephalography demonstrated normal stage II-III sleep architecture without epileptiform discharges, significant paroxysmal activity, or hemispheric asymmetry.Brain MRI revealed nonspecific right pericallosal gliosis with preserved basal ganglia and hippocampi.Follow-up contrast-enhanced MRI showed normal brain anatomy except for stable
Source: Turkish Archives of Pediatrics
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7226030008
